✨ Free AI Report
Astria Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Astria Therapeutics, Inc.
Company Research

Astria Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Astria Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Now a BioCryst subsidiary, Astria's navenibart adds injectable prophylactic capability to a hereditary angioedema portfolio, but integration execution risk and market competition remain. Pre-acquisition, Astria demonstrated clinical-stage momentum with positive Phase 1b/2 proof-of-concept data for its lead HAE program. However, the company's status as a private acquisition target limits.

What is Astria Therapeutics, Inc.'s industry? Astria Therapeutics, Inc. (astriatx.com) operates in Orphan Drugs. AskCyborg classifies Astria Therapeutics, Inc. under Orphan Drugs in its company registry.

Astria Therapeutics is a biopharmaceutical company developing life-changing therapies for patients with rare and niche allergic and immunological diseases.

6/ 10Solid

Cyborg Score thesis

Now a BioCryst subsidiary, Astria's navenibart adds injectable prophylactic capability to a hereditary angioedema portfolio, but...

Read the full analyst-debate transcript →
Industry Orphan Drugs
6 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Astria Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Astria Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Astria Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Astria Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Astria Therapeutics, Inc. Overview

Pro stress-test →

Astria Therapeutics is a biopharmaceutical company developing life-changing therapies for patients with rare and niche allergic and immunological diseases.

Strategic Profile

Pro stress-test →

The company's lead product candidate is STAR-0215 (navenibart), a monoclonal antibody inhibitor of plasma kallikrein in Phase 1b/2 clinical trials for hereditary angioedema (HAE). Navenibart is a late-stage, long-acting plasma kallikrein inhibitor in Phase 3 clinical development with potential to be the first HAE therapy with every-three and every-six month dosing.

Competitive Landscape

Pro stress-test →

Astria competes in rare allergic and immunological disease treatment, with STAR-0215 for hereditary angioedema and STAR-0310 for atopic dermatitis in preclinical development. Key competitors in the HAE space include other plasma kallikrein inhibitor developers and broader rare disease therapeutics companies.

Industry Context

Astria Therapeutics, Inc. operates in Orphan Drugs.

Key facts

Founded: 2008 · Headquarters: Boston, Massachusetts

What the analysts stress-tested

The top findings that survived the multi-agent debate for Astria Therapeutics, Inc..

  • Navenibart targets hereditary angioedema, a rare disease affecting fewer than 10,000 patients in the US; successful Phase 3 advancement could capture significant unmet demand in HAE management.
  • STAR-0310, the second program, targets atopic dermatitis via OX40 antagonism in preclinical development; success would expand Astria's addressable market beyond rare diseases into widespread immunological conditions.

Recent developments

Material events tracked by the AskCyborg corpus.

  • 2025Positive Phase 1b/2 proof-of-concept data announced for STAR-0215 (navenibart) in hereditary angioedema
  • September 2021Company renamed from Catabasis Pharmaceuticals to Astria Therapeutics
Get alerted when Astria Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Kalvista PharmaceuticalsDevelops small-molecule plasma kallikrein inhibitors for HAE→Ionis PharmaceuticalsDevelops antisense and genetic medicines including HAE therapies→Takeda Pharmaceutical Company LimitedDevelops Takhzyro (lesinurad), a plasma kallikrein inhibitor for HAE prophylaxis; market leader in hereditary angioedema treatment→CSL LimitedDevelops Andembry (garadacimab-gxii), a monoclonal antibody targeting factor XIIa for HAE prophylaxis→Pharming Group N.V.Develops Ruconest (C1 esterase inhibitor recombinant) for treating acute HAE attacks→Pharvaris B.V.Develops Factor XII/plasma kallikrein pathway inhibitors for HAE and other rare diseases→

Compare Astria Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Astria Therapeutics, Inc. operates in Orphan Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Orphan Drugs research →
NEW · MCP server

Ask your AI assistant about Astria Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Astria Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Astria Therapeutics, Inc. do this quarter?”
“Is Astria Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Astria Therapeutics, Inc. do?+
Astria Therapeutics is a biopharmaceutical company developing life-changing therapies for patients with rare and niche allergic and immunological diseases.
What is Astria Therapeutics, Inc.'s Cyborg Score?+
Astria Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Astria Therapeutics, Inc.'s main competitors?+
Named competitors include Kalvista Pharmaceuticals, Ionis Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL Limited. The full competitive landscape is in the AskCyborg report.
How can I get the full Astria Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Astria Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Astria Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Orphan Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Takeda Pharmaceutical Company Limited8CSL Limited7Pharming Group N.V.